Treatment with HER-2 antibody trastuzumab, a phosphatidylinositol 3-kinase inhibitor, or a MEK inhibitor abolished the tumorigenic capacity of the EBV-infected breast cancer cells, indicating the critical role of HER2/HER3 signaling. This evidence concerns the gene ERBB2 and breast carcinoma.